Results 131 to 140 of about 5,260,709 (398)

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells

Molecular Oncology, EarlyView.
Loss of the frequently mutated chromatin remodeler ARID1A, a subunit of the SWI/SNF cBAF complex, results in less open chromatin, alternative splicing, and the failure to stop cells from progressing through the cell cycle after DNA damage in bladder (cancer) cells. Created in BioRender. Epigenetic regulators, such as the SWI/SNF complex, with important
Rebecca M. Schlösser, Florian Krumbach, Eyleen Corrales, Geoffroy Andrieux, Christian Preisinger, Franziska Liss, Alexandra Golzmann, Melanie Boerries, Kerstin Becker, Ruth Knüchel, Stefan Garczyk, Bernhard Lüscher   +11 more
wiley   +1 more source

Germline variants in CDKN2A wild‐type melanoma prone families

Molecular Oncology, EarlyView.
Among melanoma‐prone families, wild‐type for CDKN2A and CDK4, some have pathogenic variants in genes not usually linked to melanoma. Furthermore, rare XP‐related variants and variants in MC1R are enriched in such families. Germline pathogenic variants in CDKN2A are well established as an underlying cause of familial malignant melanoma. While pathogenic
Gjertrud T. Iversen, Marie Loeng, Amalie Lund Holth, Per E. Lønning, Jürgen Geisler, Stian Knappskog   +5 more
wiley   +1 more source

ShcD adaptor protein drives invasion of triple negative breast cancer cells by aberrant activation of EGFR signaling

Molecular Oncology, EarlyView.
We identified adaptor protein ShcD as upregulated in triple‐negative breast cancer and found its expression to be correlated with reduced patient survival and increased invasion in cell models. Using a proteomic screen, we identified novel ShcD binding partners involved in EGFR signaling pathways.
Hayley R. Lau, Hayley S. Smith, Begüm Alural, Claire E. Martin, Laura A. New, Manali Tilak, Sara L. Banerjee, Hannah N. Robeson, Nicolas Bisson, Anne‐Claude Gingras, Jasmin Lalonde, Nina Jones   +11 more
wiley   +1 more source

Three Years Survival Rate of Epithelial Ovarian Cancer Patients in Dr. Kariadi Hospital, Semarang, Central Java [PDF]

, 2016
Objectives: to determine the association between prognostic factors of ovarian cancer with a 3-years survival rate of epithelial ovarian cancer patients.Material and Method: Retrospective cohort study was conducted in 90 patients (during 2012) at Dr ...
Damayanti, I. N. (Indah), Kusumastuti, E. H. (Etty), Yulianti, I. (Indra)   +2 more
core  

Human epididymis protein 4 (HE4) in benign and malignant diseases [PDF]

, 2012
Background: Human epididymis protein 4 (HE4) is described as a useful new biomarker in ovarian cancer. As HE4 is neither tumor nor organ specific, we intensively investigated the occurrence of this protein in female and male patients with various benign ...
Anastasi, Anastasi, Andersen, Andersen, Bast, Bast, Drapkin, Drapkin, Duffy, Duffy, Escudero, Escudero, Galgano, Galgano, Heintz, Heintz, Hellstrom, Hellstrom, Hellstrom, Hellstrom, Holcomb, Holcomb, Huhtinen, Huhtinen, Jacob, Jacob, Jacobs, Jacobs, Kurman, Kurman, Liu, Liu, Montagnana, Montagnana, Moore, Moore, Nolen, Nolen, Tuxen, Tuxen   +39 more
core   +1 more source

Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer

Frontiers in Pharmacology, 2019
Objective: Apolipoprotein A1 (ApoA1) is remarkably decreased in serum and ovarian tissues of ovarian cancer patients. ApoA1 and ApoA1 mimetic peptides can sequestrate pro-inflammatory phospholipids, some of which are known to activate a variety of ...
Aline T. Marinho, Aline T. Marinho, Haonan Lu, Sofia A. Pereira, Sofia A. Pereira, Emília Monteiro, Emília Monteiro, Hani Gabra, Chiara Recchi   +8 more
doaj   +1 more source

Statistical approaches using longitudinal biomarkers for disease early detection: A comparison of methodologies [PDF]

arXiv, 2019
Early detection of clinical outcomes such as cancer may be predicted based on longitudinal biomarker measurements. Tracking longitudinal biomarkers as a way to identify early disease onset may help to reduce mortality from diseases like ovarian cancer that are more treatable if detected early.
arxiv  

Time, the final frontier

Molecular Oncology, EarlyView.
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain, Michal Dibus, Omkar Joshi, Guillaume Jacquemet   +3 more
wiley   +1 more source

LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors

Cell Communication and Signaling
Liver Kinase B1 (LKB1), encoded by Serine-Threonine Kinase 11 (STK11), is a master kinase that regulates cell migration, polarity, proliferation, and metabolism through downstream adenosine monophosphate-activated protein kinase (AMPK) and AMPK-related ...
Charles B. Trelford, Trevor G. Shepherd
doaj   +1 more source

The epidemiology of ovarian cancer [PDF]

International Journal of Gynecological Cancer, 2001
The overall mortality from epithelial ovarian cancer has changed little over the past 20 years. Despite the widely heralded introduction of new chemotherapy agents such as the taxanes and increased interest in the possibility of screening for early-stage disease the overall 5-year survival rate remains static at about 30%.
Edmondson, R J, Monaghan, J M
openaire   +3 more sources